BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25434353)

  • 1. Epothilones: From discovery to clinical trials.
    Forli S
    Curr Top Med Chem; 2014; 14(20):2312-21. PubMed ID: 25434353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and Activity of Epothilone D.
    Cheng H; Huang G
    Curr Drug Targets; 2018; 19(15):1866-1870. PubMed ID: 30073925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis & antitumor activity of epothilones B and D and their analogs.
    Cheng H; Huang G
    Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
    Fumoleau P; Coudert B; Isambert N; Ferrant E
    Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical investigations with epothilones in breast cancer models.
    Burris HA
    Semin Oncol; 2008 Apr; 35(2 Suppl 2):S15-21; quiz S39. PubMed ID: 18410795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
    Fojo T; Menefee M
    Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity through semisynthesis: the chemistry and biological activity of semisynthetic epothilone derivatives.
    Altmann KH; Gaugaz FZ; Schiess R
    Mol Divers; 2011 May; 15(2):383-99. PubMed ID: 21197573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of isotopically labeled epothilones.
    Ganesh T; Brodie PJ; Banerjee A; Bane S; Kingston DG
    J Labelled Comp Radiopharm; 2014 Feb; 57(2):78-81. PubMed ID: 24307484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
    Altmann KH; Memmert K
    Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and antitumor activity of epothilone B.
    Cheng H; Huang H; Huang G
    Eur J Med Chem; 2018 Sep; 157():925-934. PubMed ID: 30149324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
    Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
    Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
    Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
    Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
    Villegas C; González-Chavarría I; Burgos V; Iturra-Beiza H; Ulrich H; Paz C
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of new functionalized epothilones for prodrug design and tumor targeting.
    Dietrich SA; Riediker L; Gertsch J; Altmann KH
    Chimia (Aarau); 2010; 64(3):136-9. PubMed ID: 21140905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in the study of tubulin inhibitors].
    Shang H; Pan L; Yang S; Chen H; Cheng MS
    Yao Xue Xue Bao; 2010 Sep; 45(9):1078-88. PubMed ID: 21351562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CENP-E checks in microtubule-drug resistance.
    Chanel-Vos C; Giannakakou P
    Cell Cycle; 2010 Apr; 9(8):1456. PubMed ID: 20421712
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the microtubules in breast cancer beyond taxanes: the epothilones.
    Cortes J; Baselga J
    Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.